[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"osteoporosis-fracture\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:osteoporosis-fracture":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,76,106],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100558441","peripheral-mononuclear-cells-to-screen-monitor-and-stratify-the-population-at-risk-of-osteoporosis-and-fractures-100558441",false,"NCT06551155","Peripheral Mononuclear Cells to Screen, Monitor and Stratify the Population at Risk of Osteoporosis and Fractures","Identification, Monitoring, and Classification of Patients at Risk of Osteoporosis and Fractures Using a Method Based on the Use of Mononuclear Cells From Peripheral Blood","DISCERN","Inclusion Criteria:\n\n* Healthy patients (at risk and undergoing periodic follow-up and\u002For attending outpatient visits for preventive screening)\n* Osteopenic patients with an available DXA\n* Osteoporotic patients (fractured and non-fractured) with an available DXA or, for fractured patients, a DXA prescribed as part of clinical practice\n* Aged ≥ 40 years of both sexes\n* Body Mass Index (BMI) between 18.5 and 29.9\n\nExclusion Criteria:\n\n* Hematopoietic system disorders (hemolytic, aplastic, and neoplastic anemias)\n* Coagulation disorders (hereditary or secondary to other disorders)\n* Infections (including HIV-HBV-HCV positivity)\n* Neoplastic diseases (primary and\u002For secondary tumors)\n* Pregnancy or breastfeeding\n* Alcohol consumption (\\>20 g of alcohol per day currently or in the past)\n* Smoking (\\>10 cigarettes per day, currently or in the past)\n* Diabetes\n* Treatment with therapeutic agents that may interfere with hematopoiesis (corticosteroids, immunosuppressive agents, cytotoxic drugs)","ALL","40 Years",{"count":20,"type":21},120,"ESTIMATED","OBSERVATIONAL","Osteoporosis (OP) is one of most common age-associated and chronic metabolic bone diseases, featured by a decrease of bone mineral density (BMD) that increases the risk of bone fractures.OP guidelines agree that Dual-X-ray Absorptiometry (DXA) is the gold standard for BMD assessment, but for the different OP stages screening and diagnosis, BMD by itself is not an accurate predictor. Thus, OP is often misdiagnosed. Aim of the this study is to improve a tool for OP diagnosis based on the ability of circulating peripheral blood mononuclear cells (PBMCs) to maintain or not their in vitro viability (IRCCS Istituto Ortopedico Rizzoli European patent n.3008470 March 21, 2018) for the measurement of the different OP severity levels, also considering specific gender related differences.",[25,26,27],"Osteoporosis","Osteopenia","Osteoporosis Fracture",[29,30,31],"peripheral blood mononuclear cells","screening","diagnosis","RECRUITING","2026-05-25",{"date":35,"type":36},"2026-05-28","ACTUAL",{"date":38,"type":36},"2024-08-05",{"date":40,"type":21},"2027-02-20",{"name":42,"class":43},"Istituto Ortopedico Rizzoli","OTHER",2,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100605641","phase-4-the-effect-of-semaglutide-on-bone-health-100605641","NCT07165158","The Effect of Semaglutide on Bone Health","The Effect of Semaglutide on Osteoporotic Fractures in Patients With Type 2 Diabetes","Inclusion Criteria:\n\n1. Type 2 diabetes (according to WHO diagnostic criteria),\n2. Age range: 50 to ≦75 years,\n3. Glycosylated hemoglobin (HbA1c): 6.5 to ≦9.0%,\n4. Bone mineral density (lumbar spine, hip, or femoral neck) T-score \\\u003C -1, or history of fragility fractures (hip, vertebral, distal forearm, or proximal humerus fractures) within three years before screening,\n5. No use of antidiabetic medications in 8 weeks prior to enrollment (excluding metformin).\n\nExclusion Criteria:\n\n1. Bone mineral density (lumbar spine, hip, or femoral neck) T-score \\\u003C -2.5,\n2. History of secondary osteoporosis,\n3. Serious liver dysfunction or chronic kidney disease (aspartate aminotransferase (AST) or alanine transaminase (ALT) \\> 2.5 times the upper limit of the normal reference, or estimated glomerular filtration rate (eGFR) \\\u003C 45 ml\u002Fmin\u002F1.73㎡),\n4. History of malignant tumors,\n5. Received strong anti-osteoporosis medications such as bisphosphonates, denosumab, or teriparatide within the past 2 years,\n6. History of pancreatitis or triglyceride levels \\>5.6 mmol\u002FL;\n7. Family history of medullary carcinoma.","50 Years","75 Years",{"count":55,"type":21},150,"INTERVENTIONAL",[58],"PHASE4","Semaglutide has effects that include lowering blood sugar, reducing weight, and improving cardiovascular and renal outcomes, and it is now widely used in clinical practice. Given that weight loss is associated with bone loss, its effect on bone health has recently raised concerns. Therefore, the goal of this clinical trial is to learn the effect of semaglutide on bone mineral density and fractures in patients with type 2 diabetes.\n\nThe investigators will compare semaglutide combined with metformin to metformin alone to see if semaglutide treatment has effects on bone mineral density and bone turnover markers in patients with type 2 diabetes after 12 months.\n\nThe intervention group will receive semaglutide combined with metformin for 12 months, while the control group will receive metformin alone for the same duration. After 12 months of treatment, the investigators will compare the bone mineral density, fracture incidence, and levels of bone turnover markers between the two groups.",[25,27,61],"T2DM",[63,64,61],"antidiabetic drug","osteoporosis fracture","NOT_YET_RECRUITING","2025-09-11",{"date":68,"type":36},"2025-09-17",{"date":70,"type":21},"2025-09-15",{"date":72,"type":21},"2026-12-31",{"name":74,"class":43},"The First Affiliated Hospital of Xiamen University",1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":83,"minAge":4,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":86,"conditions":87,"keywords":90,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":75},"100556483","new-biomarkers-and-therapeutic-targets-in-osteoporosis-via-omics-technologies-100556483","NCT06525688","New Biomarkers and Therapeutic Targets in Osteoporosis Via Omics Technologies","Identification of New Biomarkers and Potential Therapeutic Targets in Clinical Osteoporosis Using Omics Technologies","Inclusion Criteria:\n\n* Postmenopausal Female Patients with osteoporotic subcapital femoral neck fracture (Arm 1)\n* Postmenopausal Female Patients with hip osteoarthritis that will undergo Total Hip Replacement (Arm 2)\n\nExclusion Criteria:\n\n* Patients that have undergone before osteoporotic fractures\n* Patients with severe cardiovascular, pulmonary, autoimmune, or urinary system conditions","FEMALE",{"count":85,"type":21},60,"This study aims to discover novel biomarkers and therapeutic targets for osteoporosis through the use of advanced omics technologies, including proteomics and metabolomics. By analyzing bone and plasma samples from patients with osteoporosis, the research seeks to understand the underlying mechanisms of the disease and identify potential diagnostic and therapeutic biomarkers.",[88,27,89],"Osteoporosis, Postmenopausal","Osteoporosis, Severe",[25,91,92,93,94,95,96],"Osteoarthritis","Hip fracture","Postmenopausal Osteoporosis","Proteomics","Metabolomics","Osteoporotic Hip Fracture","2024-07-24",{"date":99,"type":36},"2024-07-29",{"date":101,"type":36},"2024-07-03",{"date":103,"type":21},"2025-12-30",{"name":105,"class":43},"National and Kapodistrian University of Athens",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":113,"enrollmentInfo":114,"targetDuration":4,"studyType":56,"phases":116,"briefSummary":118,"conditions":119,"keywords":123,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":75},"100545234","development-and-validation-of-a-postoperative-re-fracture-risk-model-for-osteoporotic-spinal-fractures-100545234","NCT06379243","Development and Validation of a Postoperative Re-fracture Risk Model for Osteoporotic Spinal Fractures","Development and Validation of a Postoperative Re-fracture Risk Model for Osteoporotic Spinal Fractures: a Multicenter Prospective Cohort Study","Inclusion Criteria:\n\n* Patients diagnosed with osteoporotic vertebral fractures of the thoracic and lumbar level with reference to the 2022 edition of the Osteoporotic Fractures Guidelines (2022 edition);\n* The presence of bone marrow edema or hemorrhage (acute fracture) in the fractured vertebrae is clearly defined by MR examination, and the responsible vertebrae is treated with PVP \u002F PKP;\n* Number of fractured vertebrae: 1-3 vertebral compression fractures (including old fractures).\n\nExclusion Criteria:\n\n* History of severe scoliosis, vertebroplasty, or internal spinal fixation;\n* Presence of spinal infection and malignant neoplastic disease;\n* Presence of mental disease, cognitive impairment, or critical illness (e.g., severe cardiac or cerebrovascular disease).","90 Years",{"count":115,"type":21},560,[117],"NA","In this project, IDEAL-IQ technology and PDFF and R2\\* image-based imaging methods are used to analyze the intrinsic relationship between preoperative vertebral bone marrow fat content, magnetic susceptibility properties of bone tissue and bone strength (bone volume and bone mass), to explore the mechanism of vertebral re-fracture after PVP \u002F PKP, and to explore the imaging markers for the risk of postoperative vertebral re-fracture after PVP \u002F PKP. To construct a precise and individualized risk assessment model of vertebral re-fracture after PVP\u002F PKP by combining clinical risk factors, preoperative quantitative MRI parameters (PDFF, R2\\*) and imaging characteristics, so as to achieve the goal of objectively and accurately evaluating the risk of vertebral re-fracture at the early stage of the postoperative period (1 year).",[27,120,121,122],"Osteoporosis Vertebral","Compression Fracture","Perform PVP \u002F PKP Treatment",[124,125,126],"osteoporosis","spinal vertebral fractures","PVP \u002F PKP treatment","2024-04-21",{"date":129,"type":36},"2024-04-23",{"date":131,"type":36},"2023-12-01",{"date":133,"type":21},"2027-12-31",{"name":135,"class":43},"The Seventh Affiliated Hospital of Sun Yat-sen University"]